



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/535, 9/20, 9/48, 47/36</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/51239</b> <b>(43) International Publication Date:</b> 14 October 1999 (14.10.99)
<b>(21) International Application Number:</b> PCT/US99/07228 <b>(22) International Filing Date:</b> 1 April 1999 (01.04.99) <b>(30) Priority Data:</b> 60/080,925 7 April 1998 (07.04.98) US <b>(71) Applicant:</b> DU PONT PHARMACEUTICALS COMPANY [US/US]; 974 Centre Road, WR-1ST18, Wilmington, DE 19807 (US). <b>(72) Inventors:</b> MAKOOI-MOREHEAD, William, T.; 1 Virginia Lane, Wallingford, PA 19086 (US). BUEHLER, John, D.; 1111 Hunt Seat Drive, Ambler, PA 19002 (US). LAND-MANN, Brian, R.; Apartment A, 220 Willow, Hoboken, NJ 07030 (US). <b>(74) Agent:</b> VANCE, David, H.; Du Pont Pharmaceuticals Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).		<b>(81) Designated States:</b> AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, ZA, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> FORMULATION OF FAST-DISSOLVING EFAVIRENZ CAPSULES OR TABLETS USING SUPER-DISINTEGRANTS		
<b>(57) Abstract</b>  The present invention provides improved oral dosage form formulations of efavirenz that are useful in the inhibition of human immunodeficiency virus (HIV), the prevention or treatment of infection by HIV, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS). In particular, the present invention relates to compressed tablets or capsules comprising efavirenz that contain one or more disintegrants that enhance the dissolution rate of the efavirenz in the gastrointestinal tract thereby improving the rate and extent of absorption of efavirenz in the body. The present invention also relates to the process of making such tablets or capsules.		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5

TITLE

FORMULATION OF FAST-DISSOLVING EFAVIRENZ CAPSULES OR TABLETS  
USING SUPER-DISINTEGRANTS

FIELD OF THE INVENTION

10       The present invention provides improved oral dosage form  
formulations of efavirenz that are useful in the inhibition of  
human immunodeficiency virus (HIV), the prevention or  
treatment of infection by HIV, and in the treatment of the  
resulting acquired immune deficiency syndrome (AIDS). In  
15       particular, the present invention relates to compressed  
tablets or capsules comprising efavirenz that contain one or  
more disintegrants that enhance the dissolution rate of the  
efavirenz in the gastrointestinal tract thereby improving the  
rate and extent of absorption of efavirenz in the body. The  
20       present invention also relates to the process of making such  
tablets or capsules.

BACKGROUND OF THE INVENTION

      In the dose titration of a patient, the objective is to  
25       attain and maintain a blood level of drug substance that  
exceeds the minimum effective level required for response but  
does not exceed the minimum toxic level. Absorption of a drug  
from an oral dosage form such as a tablet or a capsule can be  
affected by properties of the formulation and its method of  
30       manufacture. This is particularly true when the drug has low  
solubility in water, has a hydrophobic nature, and/or is  
administered in high therapeutic doses. In such cases,  
dissolution of the drug from the dosage form in the  
gastrointestinal tract can be the limiting factor that  
35       determines the rate and extent of absorption of drug into the  
body. Changes in the composition and/or method of manufacture  
of the dosage form can affect the dissolution rate.

5           An active area of research is in the discovery of new  
methods of drug formulation. Drug release from a solid dosage  
form can be enhanced by addition of materials referred to as  
disintegrants. Disintegrants are substances or a mixture of  
substances added to the drug formulation that facilitate the  
10 breakup or disintegration of the tablet or capsule contents  
into smaller particles that dissolve more rapidly than in the  
absence of the disintegrant (Handbook of Pharmaceutical  
Excipients, Ainley Wade and Paul J. Weller eds., 2d ed. 1994;  
The Theory and Practice of Industrial Pharmacy, Leon Lachman,  
15 Herbert A. Lieberman, and Joseph L. Kanig eds., 3rd ed. 1986;  
Disintegrating Agents in Hard Gelatin Capsules, John E.  
Botzolakis and Larry L. Augsburger, Drug Development and  
Industrial Pharmacy 14(1), 29-41 1988). Materials that serve  
as disintegrants include starches, clays, celluloses, algin,  
20 gums and cross-linked polymers. A group of disintegrants  
referred to as "super-disintegrants" are generally used at a  
low level in the solid dosage form, typically 1 to 10% by  
weight relative to the total weight of the dosage unit.  
Examples of super-disintegrants are croscarmellose,  
25 crospovidone and sodium starch glycolate, which represent  
examples of a cross-linked cellulose, a cross-linked polymer  
and a cross-linked starch, respectively. EP 0,301,006  
describes the use of super-disintegrants to enhance the  
dissolution properties of tablet and capsule formulations  
30 containing methylprednisolone, a glucocorticoid steroid.

It is desirable to develop formulations where the tablet  
or capsule disintegrates rapidly and the pharmaceutical agent  
dissolves readily. This is especially important where the  
pharmaceutical agent is highly insoluble and/or must be  
35 administered in high-strength dosage forms.

This invention relates to new solid oral dosage form  
formulations containing the HIV drug efavirenz that enhance  
the dissolution rate of efavirenz in the gastrointestinal

5 tract in order to improve the rate and extent of absorption into the body, thereby improving its therapeutic effect.

#### SUMMARY OF THE INVENTION

The present invention provides improved solid dosage  
10 forms containing the non-nucleoside HIV reverse transcriptase inhibitor (NNRTI) drug efavirenz that disintegrate and dissolve rapidly thereby enhancing the therapeutic characteristics of the formulation. The present invention also provides processes for the manufacture of capsule and  
15 tablet formulations of efavirenz that allow a significantly higher strength of efavirenz to be formulated in a single capsule or tablet.

An embodiment of the present invention includes formulations and processes for manufacturing tablets or  
20 capsules containing efavirenz using a high-shear, wet granulation step where a very high level of a super-disintegrant such as sodium starch glycolate is included in the wet granulation step.

Another embodiment of the present invention uses the  
25 super-disintegrant sodium starch glycolate in both a wet granulation and a dry blending step in the manufacturing process of tablets and capsules containing efavirenz. In a preferred embodiment of the manufacturing process the quantity of the sodium starch glycolate used in the wet granulation  
30 step is in the range from about 20% to about 75% by weight relative to the total dry weight of materials being granulated in the wet granulation step. More preferably the super-disintegrant component in the wet granulation step is in the range from about 20% to about 55% by weight relative to the  
35 total dry weight of the materials being granulated in the wet granulation step.

In another embodiment of the present invention the range for the efavirenz in the wet granulation step can vary from

5 about 25% to about 80% by weight relative to the total dry weight of the materials being granulated in the wet granulation step. More preferably the drug substance component will range from about 45% to about 80% by weight relative to total dry weight of the ingredients in the wet  
10 granulation step.

In the present invention a surfactant such as sodium lauryl sulfate is preferably used in the wet granulation step of the process for the manufacture of the capsules or tablets of the present invention. The sodium lauryl sulfate is  
15 preferably dissolved in the wet granulating fluid. Most preferably the sodium lauryl sulfate will range from about 0.1% to about 5% by weight relative to the total dry weight of the materials being granulated in the wet granulation step.

20 DETAILED DESCRIPTION OF THE INVENTION

The present invention provides improved oral dosage form formulations of efavirenz that are useful in the inhibition of human immunodeficiency virus (HIV), the prevention or treatment of infection by HIV, and in the treatment of the  
25 resulting acquired immune deficiency syndrome (AIDS). In particular, the present invention relates to compressed tablets or capsules comprising efavirenz that contain one or more disintegrants that enhance the dissolution rate of the efavirenz in the gastrointestinal tract thereby improving the  
30 rate and extent of absorption of efavirenz in the body. The present invention also relates to the process of making such tablets or capsules.

The active ingredient of the formulation of the present invention is the NNRTI efavirenz, which is present in a  
35 therapeutically effective amount. Methods for the manufacture of efavirenz are disclosed in U.S. Patent 5,519,021. The disclosure of U.S. Patent 5,519,021 in its entirety is hereby incorporated by reference. Efavirenz is (s)6-chloro-4-

5 (cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one.

In addition to the active ingredient, solid dosage forms contain a number of additional ingredients referred to as excipients. These excipients include among others diluents, binders, lubricants, glidants and disintegrants. Diluents are used to impart bulk to the formulation to make a tablet a practical size for compression. Examples of diluents are lactose and cellulose. Binders are agents used to impart cohesive qualities to the powdered material ensuring the tablet will remain intact after compression, as well as improving the free-flowing qualities of the powder. Examples of typical binders are lactose, starch and various sugars. Lubricants have several functions including preventing the adhesion of the tablets to the compression equipment and improving the flow of the granulation prior to compression or encapsulation. Lubricants are in most cases hydrophobic materials. Excessive use of lubricants can result in a formulation with reduced disintegration and/or delayed dissolution of the drug substance. Glidants are substances that improve the flow characteristics of the granulation material. Examples of glidants include talc and colloidal silicon dioxide. Disintegrants are substances or a mixture of substances added to a formulation to facilitate the breakup or disintegration of the solid dosage form after administration. Materials that serve as disintegrants include starches, clays, celluloses, alginates, gums and cross-linked polymers. A group of disintegrants referred to as "super-disintegrants" generally are used at a low level in the solid dosage form, typically 1% to 10% by weight relative to the total weight of the dosage unit. Croscarmellose, crospovidone and sodium starch glycolate represent examples of a cross-linked cellulose, a cross-linked polymer and a cross-linked starch, respectively. Sodium starch glycolate swells seven- to twelve-fold in less than 30

5 seconds effectively disintegrating the granulations that contain it. Granulation refers to a mixing technique by which the overall particle size of a formulation is increased through the permanent aggregation of smaller particles. Wet granulation refers to granulation that is accomplished by  
10 wetting the smaller particles so they tack to one another. The newly-formed larger particles remain intact after drying. In dry granulation, larger particles are formed as a result of the compaction of the dry ingredients, followed by milling of this compacted material into suitably sized particles.

15 An embodiment of the present invention is a formulation and a process for manufacturing tablets or capsules using a high-shear, wet granulation step in which a very high level of a super-disintegrant such as sodium starch glycolate is included, followed by a dry blending step that incorporates  
20 additional quantities of super-disintegrant. In the present invention the amount of the super-disintegrant in the wet granulation step of the manufacturing process is preferably in the range of about 20% to about 75% by weight relative to the total dry weight of the materials used in the wet granulation  
25 step. More preferably the super-disintegrant component will range from about 20% to about 55% by weight relative to the total dry weight of all of the ingredients in the wet granulation step of the manufacturing process. In general, the range for the HIV reverse transcriptase inhibitor in the  
30 wet granulation step can vary from about 25% to about 80% by weight relative to the total dry weight of all of the ingredients in the wet granulation step of the manufacturing process. More preferably the drug substance component will range from about 45% to about 80% by weight relative to the  
35 total dry weight of all of the ingredients in the wet granulation step of the manufacturing process. Also included in the wet granulation step is a surfactant such as sodium lauryl sulfate, or another material that improves the



5 wettability of the drug. Preferably the surfactant component  
will range from about 0.1% to about 5% by weight relative to  
the total weight of ingredients in the formulation. After the  
wet granulation step, the material is dried, milled, and dry  
blended with other ingredients such as diluents, glidants,  
10 disintegrants, and lubricants. The result of the dry blending  
step is then filled into gelatin capsule shells or compressed  
into tablets. Gelatin capsules may contain the active  
ingredient and powdered carriers such as lactose, starch,  
cellulose derivatives, magnesium stearate, stearic acid, and  
15 the like. Similar diluents can be used to make compressed  
tablets. Both capsules and tablets can be manufactured as  
sustained release products to provide for continuous release  
of medication over a period of hours. Compressed tablets can  
be sugar coated or film coated to mask any unpleasant taste  
20 and to protect the tablet from the atmosphere, or enteric  
coated for selective disintegration in the gastrointestinal  
tract. Technology for the formation of solid dosage forms  
such as capsules and compressed tablets, that utilize  
conventional pharmaceutical manufacturing equipment for their  
25 purpose, is described in detail in Remington's Pharmaceutical  
Sciences (Alfonso R. Gennaro ed., ch. 89, 18th ed. 1990).

In one aspect of the present invention, it was discovered  
that the sodium starch glycolate acts as a highly swellable  
carrier material onto which the efavirenz adheres during the  
30 wet granulation step of the process for the manufacture of  
tablets or capsules containing efavirenz. Granulation refers  
to a processing technique by which the overall particle size  
of a formulation is increased through the permanent  
aggregation of smaller particles. Wet granulation refers to  
35 granulation that is accomplished by wetting the smaller  
particles so they tack to one another. The newly-formed  
larger particles remain intact after drying. In the dry  
blending step of the process for the manufacture of tablets or

5 capsules containing efavirenz, extragranular materials are added to the granulation to impart other improved characteristics such as flow and lubricity. The granulation is evenly blended throughout the mixture.

The adherence of the drug efavirenz substance particles to the hydrated disintegrant sodium starch glycolate is accomplished by intimate mixing in the wet granulation step. In an embodiment of the present invention the quantity of sodium starch glycolate used in the wet granulation step is significantly higher than is typically used. In the present invention the wet granulation preferably contains about 20% to about 75% by weight sodium starch glycolate relative to the total dry weight of the ingredients of the wet granulation step, as opposed to the 1-10% that is used in a typical wet granulation step (Handbook of Pharmaceutical Excipients, 20 Ainley Wade and Paul J. Weller eds., 2d ed. 1994; The Theory and Practice of Industrial Pharmacy, Leon Lachman, Herbert A. Lieberman, and Joseph L. Kanig eds., 3rd ed. 1986; Disintegrating Agents in Hard Gelatin Capsules, John E. Botzolakis and Larry L. Augsburger, Drug Development and 25 Industrial Pharmacy 14(1), 29-41 1988). During the wet granulation, efavirenz drug substance particles are attached to the surface of the sodium starch glycolate particles. When these granules are exposed to the fluid in the gastrointestinal tract following the disintegration of the solid dosage form, the sodium starch glycolate rapidly swells and presents the attached efavirenz drug substance particles to the fluid allowing for rapid dissolution of the efavirenz. 30

The present invention provides capsule or compressed tablet pharmaceutical dosage forms comprising a therapeutically effective amount of efavirenz and comprising one or more disintegrants in an amount greater than about 10% by weight relative to the total weight of the contents of the capsule or the total weight of the tablet. 35

5       The disintegrant used in the present invention is preferably selected from the group comprising modified starches, croscarmallose sodium, carboxymethylcellulose calcium and crospovidone.

10       The preferred disintegrant in the present invention is a modified starch.

      The more preferred disintegrant in the present invention is the modified starch sodium starch glycolate.

15       In the present invention the capsule formulation contains efavirenz present in an amount from about 5 to about 1000 mg per capsule.

      It is preferred in the present invention that the capsule formulation contain from about 5 to about 500 mg of efavirenz per capsule.

20       It is preferred in the present invention that the capsule formulation contain from about 500 to about 1000 mg of efavirenz per capsule.

      It is preferred in the present invention that the capsule formulation contain from about 25 to about 350 mg of efavirenz per capsule.

25       It is preferred in the present invention that the capsule formulation contain from about 50 to about 200 mg of efavirenz per capsule.

30       The compressed tablet of the present invention contains efavirenz in an amount from about 5 to about 800 mg per tablet.

      The present invention provides for a pharmaceutical dosage form comprising:

- (a) a therapeutically effective amount of efavirenz;
- (b) a surfactant;
- 35       (c) a disintegrant;
- (d) a binder;
- (e) a diluent;
- (f) a lubricant;

- 5 (g) a glidant; and  
(h) optionally additional pharmaceutically acceptable  
excipients;

wherein the disintegrant is selected from modified starches,  
croscarmallose sodium, carboxymethylcellulose calcium and  
10 crospovidone and is present in an amount greater than about  
10% by weight of the total dry weight of the capsule contents  
or the compressed tablet.

Another embodiment of the present invention provides a  
method for manufacturing a solid dosage form comprising the  
15 steps of:

- (a) wet granulating the efavirenz and the intragranular  
sodium starch glycolate in a high-shear granulator  
using an aqueous solution of sodium lauryl sulfate;  
(b) drying result of step (a);  
20 (c) milling result of step (b);  
(d) dry blending result of step (c) with the  
extragranular sodium starch glycolate and additional  
pharmaceutically acceptable excipients; and  
(e) encapsulating or compressing into tablets the result  
25 of step (d).

As used herein, the following terms and expressions have  
the indicated meanings.

"Sodium starch glycolate" refers to sodium carboxymethyl  
starch.

30 "Efavirenz" refers to the pharmacologically active  
ingredient (S) 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-  
(trifluoromethyl)-2H-3,1-benzoxazin-2-one. The process for  
the synthesis of this compound is described in U.S. Patent  
Number 5,519,021, which is hereby incorporated by reference.

35 "Therapeutically effective amount" is intended to mean an  
amount of a compound sufficient to produce the desired  
pharmacological effect.

5 "Modified starch" as used herein means any of several water-soluble polymers derived from a starch (corn, potato, tapioca) by acetylation, chlorination, acid hydrolysis, or enzymatic action.

10 EXAMPLES

In the following embodiments of the invention, the below-listed quantities of drug substance and additional components are combined using standard pharmaceutical manufacturing techniques. The resulting formulations are used to fill  
15 gelatin capsule shells or compressed into tablets utilizing standard pharmaceutical manufacturing techniques.

Example 1: Wet Granulation 100 mg Capsule Formulation

Method of manufacture: The efavirenz and intragranular  
20 sodium starch glycolate are mixed and then wet granulated after adding an aqueous solution of sodium lauryl sulfate. This wet mass may then be dried in a fluid bed, tray or other suitable dryer. The dried granulation may then be milled to achieve a suitable particle size distribution and then is  
25 blended with the other ingredients. This blend is then filled into two piece hard gelatin capsule shells.

	<u>Ingredient</u>	<u>Amount per capsule</u>	<u>%</u>
	efavirenz	100 mg	39.06
30	sodium lauryl sulfate	5 mg	1.95
	lactose, hydrous	57 mg	22.26
	magnesium stearate	4 mg	1.56
	sodium starch glycolate (intragranular)	80 mg	31.25
	sodium starch glycolate (extragranular)	<u>10 mg</u>	3.91
35	Total Capsule Weight	256 mg	

5    Example 2: Wet Granulation 100 mg Capsule Formulation

Method of manufacture: The efavirenz and intragranular sodium starch glycolate are granulated using an aqueous solution of sodium lauryl sulfate. This wet mass may then be dried in a fluid bed, tray or other suitable dryer. The dried granulation may then be milled to achieve a suitable particle size distribution and then is blended with the other ingredients. This blend is then filled into two piece hard gelatin capsule shells.

15	<u>Ingredient</u>	<u>Amount per capsule</u>	<u>%</u>
	efavirenz	100 mg	21.93
	sodium lauryl sulfate	5 mg	1.10
	sodium starch glycolate (intragranular)	50 mg	10.96
	sodium starch glycolate (extragranular)	10 mg	2.19
20	lactose, hydrous	277 mg	60.75
	talc	8 mg	1.75
	colloidal silicon dioxide	4 mg	0.88
	stearic acid	2 mg	0.44
	Total Capsule Weight	456 mg	

25

Example 3: Wet Granulation 300 mg Tablet Formulation

Method of manufacture: The efavirenz, sodium starch glycolate and microcrystalline cellulose are granulated using an aqueous solution of sodium lauryl sulfate. This wet mass may then be dried in a fluid bed, tray or other suitable dryer. The dried granulation may then be milled to achieve the desired particle size distribution. This blend is compressed into tablets. These tablets may be coated if desired.

35

<u>Ingredient</u>	<u>Amount per tablet</u>	<u>%</u>
efavirenz	300 mg	50.00
sodium lauryl sulfate	12 mg	2.00

5	microcrystalline cellulose	120 mg	20.00
	sodium starch glycolate	120 mg	20.00
	lactose, hydrous	42 mg	7.00
	magnesium stearate	<u>6 mg</u>	1.00
	Total Tablet Weight	600 mg	

10

Assays were performed on capsule and tablet samples taken during the manufacturing processes described above. Analyses of the capsules and tablets utilized USP specified procedures. The dissolution test used USP methodology Apparatus 2 (paddles at 50 RPM, 900 mL of 1% sodium lauryl sulfate-distilled water solution at 37 °C).

TABLE 1

## Dissolution Assay of Capsule Formulation

20

Capsule Formulation of Example 1:

	<u>Time (minutes)</u>	<u>% Dissolved</u>
	10	82.9
	15	94.6
25	30	98.5
	45	99.3
	60	99.6

TABLE 2

## Dissolution Assay of Tablet Formulation

30

Tablet Formulation of Example 3:

	<u>Time (minutes)</u>	<u>% Dissolved</u>
	10	78.0
35	15	91.5
	30	100.0
	45	102.1
	60	102.9

5        Assays were performed to determine dosage-form uniformity  
on capsule and tablet samples taken during the manufacturing  
processes described above. Capsules and tablets were tested  
for content uniformity following USP specified guidelines.  
Results are shown in Table 3. "RSD" as used herein refers to  
10 relative standard deviation and is calculated according to USP  
guidelines.

TABLE 3  
Content Uniformity Assay

15 Capsules from Example 1:

content uniformity 100.2 +/- 1.7% (mean +/- RSD)

Tablets from Example 3:

content uniformity 104.3 +/- 0.7% (mean +/- RSD)



5

CLAIMS

What is claimed is:

1. A capsule or a compressed tablet pharmaceutical dosage form comprising a therapeutically effective amount of efavirenz and greater than about 10% by weight of a disintegrant relative to the total dry weight of the pharmaceutical dosage form.
2. A capsule or compressed tablet according to claim 1 , wherein the disintegrant is selected from modified starches, croscarmallose sodium, carboxymethylcellulose calcium and crospovidone.
3. A capsule or compressed tablet according to claim 2, wherein the disintegrant is selected from one or more modified starches.
4. A capsule or compressed tablet according to claim 3, wherein the modified starch is sodium starch glycolate.
5. A capsule or compressed tablet according to any preceding claim which is prepared using a wet granulation step containing efavirenz and one or more modified starches, wherein the modified starch is present in the wet granulation step in an amount of from about 10% to about 75% by weight relative to the total dry weight of the components of the wet granulation step.
6. A capsule or compressed tablet according to any preceding claim, wherein the modified starch is present in the wet granulation step of the manufacturing process in an amount of from about 20% to about 55% by weight relative to total dry weight of the components of the wet granulation step.

- 5 7. A capsule according to any preceding claim, wherein the  
efavirenz is present in the pharmaceutical dosage form in an  
amount of from about 5 to about 1000 mg.
- 10 8. A capsule according to any preceding claim, wherein the  
efavirenz is present in the pharmaceutical dosage form in an  
amount of from about 5 to about 500 mg.
- 15 9. A capsule according to any preceding claim, wherein the  
efavirenz is present in the pharmaceutical dosage form in an  
amount of from 500 to about 1000 mg.
- 20 10. A capsule according to any preceding claim, wherein the  
efavirenz is present in the pharmaceutical dosage form in an  
amount of from about 25 to about 350 mg.
- 25 11. A capsule according to any preceding claim, wherein the  
efavirenz is present in the pharmaceutical dosage form in an  
amount of from about 50 to about 200 mg.
- 30 12. A compressed tablet or capsule according to claim 5-11,  
wherein the wet granulation step is carried out in the  
presence of sodium lauryl sulfate.
- 35 13. A compressed tablet or capsule according to claim 12,  
wherein the sodium lauryl sulfate is present in an amount of  
about 0.1% to about 5% by weight relative to total dry weight  
of the components of the wet granulation step.
14. A compressed tablet according to claim 1, wherein the  
efavirenz is present in the pharmaceutical dosage form in an  
amount of from about 5 to about 800 mg.
15. A pharmaceutical dosage form comprising:

- 5           (a) a therapeutically effective amount of efavirenz;  
            (b) a surfactant;  
            (c) a disintegrant;  
            (d) a binder;  
            (e) a diluent;  
10           (f) a lubricant;  
            (g) a glidant; and  
            (h) optionally additional pharmaceutically acceptable  
            excipients;

            wherein the disintegrant is selected from modified starches,  
15     croscarmallose sodium, carboxymethylcellulose calcium and  
            crospovidone and such disintegrant is present in an amount  
            greater than about 10% by weight of the total dry weight of  
            the capsule contents or the compressed tablet.

20     16. A method for producing a capsule or a compressed tablet  
            pharmaceutical dosage form comprising a therapeutically  
            effective amount of efavirenz and greater than about 10% by  
            weight of sodium starch glycolate relative to the total dry  
            weight of the pharmaceutical dosage form comprising:

- 25           (a) wet granulating efavirenz and sodium starch glycolate  
            in the presence of an aqueous solution of sodium  
            lauryl sulfate;  
            (b) drying the product of step (a);  
            (c) milling the product of step (b);  
30           (d) dry blending the product of step (c) with sodium  
            starch glycolate and additional pharmaceutically  
            acceptable excipients; and  
            (e) encapsulating or compressing into tablets the product  
            of step (d).

35

            17. A method according to claim 16, wherein: (i) the sodium  
            starch glycolate of step (a) is present in an amount of from  
            about 20% to about 75% by weight relative to the dry weight of

5 all of the components of the wet granulation step; and (ii)  
the sodium starch glycolate of step (d) is present in an  
amount of from about 1% to about 10% by weight relative to the  
total dry weight of all of the components of the dry blending  
step.

10

18. A method according to claim 16, wherein: (i) the sodium  
starch glycolate of step (a) is present in an amount of from  
about 20% to about 55% by weight relative to the total dry  
weight of all of the components of the wet granulation step;  
15 and (ii) the sodium starch glycolate of step (d) is present in  
an amount of from about 2% to about 4% by dry weight relative  
to the total weight of all of the components of the dry  
blending step.

# INTERNATIONAL SEARCH REPORT

Internat. Application No. **PCT/US 99/07228**

**A. CLASSIFICATION OF SUBJECT MATTER**

A 61 K 31/535, A 61 K 9/20, A 61 K 9/48, A 61 K 47/36

According to International Patent Classification (IPC) or to both national classification and IPC **6**

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95/20389 A1 (MERCK & CO., INC.) 03 August 1995, page 28, line 4 - page 29, line 23, claims 2,6,7. --	1-4, 7- 11, 14, 15
A	WO 96/22955 A1 (MERCK & CO., INC.) 01 August 1996, pages 1,2. --	1
A	WO 96/41634 A2 (SARDINIAN ANTIVIRAL RESEARCH CONSORTIUM - SARC S.C.R.L.) 27 December 1996, claims 1,11. --	1
A	EP 0394553 A2 (DAIICHI PHARMACEUTICAL CO.,	1

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

14 July 1999

Date of mailing of the international search report

27.08.99

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentlaan 2  
NL - 2280 LV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

MOSSER e.h.

## INTERNATIONAL SEARCH REPORT

-2-

Internat: Application No  
PCT/US 99/07228

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	LTD.) 31 October 1990, claim 1. -----	

national relatif à la sécurité de brevets  
international n°

La présente annexe indique les membres de la famille de brevets relatifs aux documents de brevets cités dans le rapport de recherche international visée ci-dessus. Les renseignements fournis sont donnés à titre indicatif et n'engagent pas la responsabilité de l'Office.

[illegible]

THIS PAGE BLANK (USPTO)